Study S001129

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01505673
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 71
Start: 2012-01
Primary completion: 2016-06
Lead sponsor: Ildiko Lingvay
Conditions: Type 2 Diabetes Mellitus; Obesity
Interventions: DRUG:Liraglutide; DRUG:Saline
Results posted: TRUE

Registered primary outcomes

Glycemic Control Measured by HbA1c [6-months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017299	Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial. Vanderheiden A, JAMA internal medicine	2016	Randomized trial	PMID 27273731 DOI	cites ClinicalTrials.gov:NCT01505673; registry reference DERIVED:27273731
R0023150	Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. Vanderheiden A, The Journal of clinical endocrinology and metabolism	2016	Randomized trial	PMID 26909799 DOI	cites ClinicalTrials.gov:NCT01505673; registry reference DERIVED:26909799